SPRO Spero Therapeutics Inc
Price (delayed)
$0.725
Market cap
$40.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
-$8.06M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Highlights
The debt has declined by 22% year-on-year and by 7% since the previous quarter
The equity has dropped by 57% year-on-year and by 30% since the previous quarter
SPRO's revenue has plunged by 55% from the previous quarter and by 54% YoY
Key stats
What are the main financial stats of SPRO
Market
Valuations
Earnings
Shares outstanding
55.9M
Market cap
$40.53M
Enterprise value
-$8.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
0.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.17
Revenue
$47.98M
Gross profit
$47.98M
Operating income
-$73.36M
Net income
-$68.57M
EBIT
-$68.57M
EBITDA
-$68.56M
Free cash flow
-$23.44M
Per share
Balance sheet
Liquidity
EPS
-$1.27
EPS diluted
-$1.27
Free cash flow per share
-$0.43
Book value per share
$0.85
Revenue per share
$0.89
TBVPS
$2.05
Total assets
$110.54M
Total liabilities
$64.42M
Debt
$4.3M
Equity
$46.12M
Working capital
$58.2M
Debt to equity
0.09
Current ratio
2.19
Quick ratio
2.15
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
-142.9%
Gross margin
100%
Net margin
-142.9%
Operating margin
-152.9%
Return on assets
-48.7%
Return on equity
-95.1%
Return on invested capital
-225.2%
Return on capital employed
-111.5%
Return on sales
-142.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRO stock price
How has the Spero Therapeutics stock price performed over time
Intraday
-3.87%
1 week
3.42%
1 month
-11.82%
1 year
-48.21%
YTD
-29.61%
QTD
0.69%
Financial performance
How have Spero Therapeutics's revenue and profit performed over time
Revenue
$47.98M
Gross profit
$47.98M
Operating income
-$73.36M
Net income
-$68.57M
Gross margin
100%
Net margin
-142.9%
SPRO's revenue has plunged by 55% from the previous quarter and by 54% YoY
The gross profit has plunged by 55% from the previous quarter and by 54% YoY
Growth
What is Spero Therapeutics's growth rate over time
Valuation
What is Spero Therapeutics stock price valuation
P/E
N/A
P/B
0.86
P/S
0.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.17
The price to book (P/B) is 63% less than the 5-year quarterly average of 2.4 and 11% less than the last 4 quarters average of 1.0
The equity has dropped by 57% year-on-year and by 30% since the previous quarter
SPRO's P/S is 93% below its 5-year quarterly average of 13.0 but 6% above its last 4 quarters average of 0.8
SPRO's revenue has plunged by 55% from the previous quarter and by 54% YoY
Efficiency
How efficient is Spero Therapeutics business performance
Dividends
What is SPRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRO.
Financial health
How did Spero Therapeutics financials performed over time
SPRO's total assets is 72% higher than its total liabilities
SPRO's quick ratio has dropped by 54% year-on-year and by 19% since the previous quarter
SPRO's total assets is down by 39% YoY and by 18% QoQ
The debt is 91% smaller than the equity
The debt to equity has soared by 80% YoY and by 29% from the previous quarter
The equity has dropped by 57% year-on-year and by 30% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.